Personalized cancer vax shows promise against glioblastomas in study

A personalized cancer vaccine has shown promise against glioblastomas, the most common malignant brain tumor. In a Phase I trial, 91 percent of patients receiving the vaccine--which was created using the patient's dendritic cells--survived one year, while 55 percent lived two years and 44 percent of patients were alive for three or more years after vaccination. The majority of glioblastoma patients die within 12 to 14 months of diagnosis. The vaccine has already entered Phase II trials, and a Phase III trial is enrolling patients. Story

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.